Literature DB >> 10594329

Agonist activation and alpha-bungarotoxin inhibition of wild type and mutant alpha7 nicotinic acetylcholine receptors.

F E Kempsill1, P J Covernton, P J Whiting, J G Connolly.   

Abstract

The properties of wild type and mutant rat nicotinic alpha7 receptors expressed in Xenopus oocytes were investigated using electrophysiology and site-directed mutagenesis. When compared at individual agonist concentrations, neither the normalised nicotinic, nor acetylcholine, responses of the wild type receptors were significantly different from the corresponding responses obtained from a first extracellular domain mutant, phenylalanine(189)tyrosine (P0.05). The dissociation constants (K(D)) of the wild type (4.7 nM) and Phe(189)Tyr mutant (5.2 nM) receptors for alpha-bungarotoxin were estimated by an electrophysiological approach. The similarity of the results suggests that the mutation did not lead to a widespread disruption of structure-function relationships, although a slight change in nicotine sensitivity may have occurred. In contrast, the mutations (Tyr(190)Gln, first extracellular domain), (Glu(261)Ala, M2 region) severely compromised receptor function. An additional mutation was made in a negatively charged motif of the second extracellular domain which is conserved in homomeric nicotinic receptors. This mutation, Asp(268)Ala, also caused a loss of function. Thus the structure-function relationships in nicotinic alpha7 receptors have parallels with heteromeric nicotinic receptors, but there may also be some marked differences.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594329     DOI: 10.1016/s0014-2999(99)00646-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Identification of regions involved in the binding of alpha-bungarotoxin to the human alpha7 neuronal nicotinic acetylcholine receptor using synthetic peptides.

Authors:  Martha Marinou; Socrates J Tzartos
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

2.  Virtual screening against acetylcholine binding protein.

Authors:  Maleeruk Utsintong; Piyanuch Rojsanga; Kwok-Yiu Ho; Todd T Talley; Arthur J Olson; Kinzo Matsumoto; Opa Vajragupta
Journal:  J Biomol Screen       Date:  2011-09-28

3.  A possible role of the cholinergic and purinergic receptor interaction in the regulation of the rat urinary bladder function.

Authors:  Ágnes Jenes; Ferenc Ruzsnavszky; Andrea Telek; Gyula P Szigeti; László Csernoch
Journal:  J Muscle Res Cell Motil       Date:  2012-02-28       Impact factor: 2.698

4.  GTS-21 Protected Against LPS-Induced Sepsis Myocardial Injury in Mice Through α7nAChR.

Authors:  Weilan Kong; Kai Kang; Yang Gao; Haitao Liu; Xianglin Meng; Yanhui Cao; Songliu Yang; Wen Liu; Jiannan Zhang; Kaijiang Yu; Mingyan Zhao
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

5.  Modeling binding modes of alpha7 nicotinic acetylcholine receptor with ligands: the roles of Gln117 and other residues of the receptor in agonist binding.

Authors:  Xiaoqin Huang; Fang Zheng; Clare Stokes; Roger L Papke; Chang-Guo Zhan
Journal:  J Med Chem       Date:  2008-10-01       Impact factor: 7.446

6.  Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.

Authors:  Roger L Papke; Julia K Porter Papke
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

Review 7.  Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors.

Authors:  Roger L Papke; Nicole A Horenstein
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.